Nektar Therapeutics shares are trading higher after the company announced updated Rezpegaldesleukin efficacy data, which it says was previously incorrectly calculated by Lilly.
Portfolio Pulse from Bill Haddad
Nektar Therapeutics announced updated Rezpegaldesleukin efficacy data, which it says was previously incorrectly calculated by Lilly. This has led to a rise in Nektar's share prices.
August 07, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nektar Therapeutics' shares are trading higher after the company announced corrected Rezpegaldesleukin efficacy data.
The announcement of corrected Rezpegaldesleukin efficacy data by Nektar Therapeutics has led to a positive market reaction, causing the company's shares to trade higher. This indicates increased investor confidence in the company's product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100